Up Approx. 14% Early, Nasdaq Biotech (CMMB) Continues To Draw Buzz On Breaking News

*Sponsored StockWireNews Up Approx. 14% Early, Nasdaq Biotech (CMMB) Continues To Draw Buzz On Breaking News March 27th Greetings Readers, (Nasdaq: CMMB) is not slowing down on the other side of the opening bell. Now up approx. 14%, the company is riding high after a major announcement. Check it out: Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers Don't forget. CMMB has fewer than 17Mn shares in its float based on Finviz reporting. That means volatility potential could be heightened on a daily basis. Consider (Nasdaq: CMMB) for your watchlist quickly this morning. ----- Did you catch that red-hot rocket on Wednesday morning? My most recent profile, an NYSE American idea oozing with breakout potential did just that... It broke out. Running from an approximate 8:00AM EST valuation of $1.62 to a high of $2.41 after the bell, that under-the-radar idea ripped off a move of approximately 48%. Solid stuff, but it's not time to pack it in quite yet. Instead, I'm bringing a new breakout idea to your attention. With fewer than 17Mn shares in its float, volatility potential could be significant. A $7.00 Maxim Group analyst target may also be suggesting well over 400% potential upside from its closing valuation Wednesday. Mix in multiple press releases regarding the strong potential for a novel treatment for systemic sclerosis (SSc), and it may start making complete sense why I want you to consider this Nasdaq profile for your watchlist immediately: *Chemomab Therapeutics Ltd. (Nasdaq: CMMB)* Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed nebokitug (CM-101), a first-in-class dual activity monoclonal antibody that neutralizes CCL24 and has demonstrated disease-modifying potential. And based on multiple potential catalysts, (Nasdaq: CMMB) requires a top spot on my watchlist. Take a look: No. 1 - Volatility Potential Could Be Heightened Due To A Low Float. No. 2 - CMMB Further Confirms Potential For nebokitug As Novel Treatment For SSc. No. 3 - A Major Milestone Completed As Company Aligns With FDA On Design Of Single Phase 3 Registration Study. No. 4 - A Maxim Group Analyst Tags CMMB With A $7 Target! But more on those in a second... A Closer Look At Chemomab - Innovation & Discovery Chemomab discovered the key role of the soluble protein CCL24 in promoting liver, skin and lung fibrosis as the driver of a fibro-inflammatory vicious cycle. The Challenge Fibrosis-related diseases are a significant unmet need that dramatically affect patients' health and quality of life. Damaged tissue repairs itself through a sequence of controlled inflammatory and fibrotic processes. However, uncontrolled healing processes can create a vicious cycle of inflammation and fibrosis – an excessive, sustained, chronic inflammatory response that activates fibroblasts, and replaces functional tissue with fibrous scar tissue. CCL24 - a Key Player Regulating CCL24 is key to halting fibrosis-related conditions. Chemomab discovered that the soluble protein CCL24 plays a key role in promoting inflammation and fibrosis via a dual pathway. CCL24 promotes both the recruitment of immune cells to the damaged tissue and supports its polarization to create a pro-fibrotic environment. In parallel, CCL24 directly activates tissue fibroblasts, enhances their transition into myofibroblasts and induces the uncontrolled production of extracellular matrix. Nebokitug Therapeutic Platform Pioneering innovation to treat fibrosis-related diseases. Chemomab's lead compound, nebokitug (CM-101) is a first-in-class humanized monoclonal antibody designed to bind to and neutralize CCL24 activity. Nebokitug interferes with the main pathologies that promote fibrosis and inflammation. It is highly effective in ameliorating fibrosis, as shown across multiple in vivo, in vitro and ex vivo studies, including experimental models of liver, skin and lung fibrosis.   Chemomab has reported positive topline data from the nebokitug Phase 2 SPRING trial in patients with primary sclerosing cholangitis (PSC), a rare, potentially lethal disease of the bile ducts.   It also has demonstrated encouraging biomarker data in a Phase 2a liver fibrosis trial in patients with metabolic-associated steatohepatitis (MASH), as well as activity in multiple preclinical models of systemic sclerosis (SSc). Product Pipeline Find Sources And More: CMMB Website. CMMB Presentation. ----- And mentioned above, (Nasdaq: CMMB) has several potential catalysts to consider immediately. Check them out: No. 1 CMMB Potential Catalyst - Volatility Potential Could Be Heightened Due To A Low Float. According to info from the Finviz website, CMMB has a relatively low float. In fact, the website reports this profile to have approx. 16.57Mn shares in its float. Why is that important? It's important on one crucial level. Volatility potential. If the company provides more positive company news in the first half of 2025, could it provide a near term spark? ----- No. 2 CMMB Potential Catalyst - CMMB Further Confirms Potential For nebokitug As Novel Treatment For SSc. New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab's Nebokitug in Systemic Sclerosis Adds to Extensive Preclinical and Early Clinical Evidence that Nebokitug Interferes with Key Features of Systemic Sclerosis TEL AVIV, Israel, March 06, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), ..., today announced a new scientific presentation that further confirms the potential of nebokitug (CM-101) as a novel treatment for systemic sclerosis (SSc). The data will be presented at the 8th International Congress on Controversies in Rheumatology and Autoimmunity (CORA 2025) on March 8, 2025, in Venice, Italy. Systemic sclerosis is an autoimmune disease characterized by microvascular injury and extensive tissue fibrosis of the skin and internal organs. It is the most lethal of the systemic connective tissue diseases and lacks approved disease-modifying therapies. Nebokitug is a first-in-class monoclonal antibody that blocks the soluble protein CCL24, which has been shown to be a key driver of the pathways underlying fibro-inflammatory conditions such as SSc and primary sclerosing cholangitis (PSC). In extensive preclinical studies, blocking CCL24 reduced the inflammatory and fibrotic injury to the lung, skin and vasculature that are hallmarks of SSc pathology. An investigator-sponsored study showed that treatment with nebokitug induced strong and rapid reductions in inflammatory biomarkers in patients with acute lung Injury, a relevant model for the type of lung damage seen in SSc patients. "This new data adds to the extensive body of preclinical evidence that CCL24 is a key driver of the skin, lung and vascular manifestations of this disabling condition that lacks disease-modifying therapies," said Adi Mor, PhD, co-founder, Chief Executive Officer and Chief Scientific Officer of Chemomab. "These results further reinforce our belief, based on multiple preclinical and patient sample studies and the positive results from our Phase 2 PSC trial, that nebokitug has substantial potential as a treatment for SSc. Chemomab has an open U.S. IND for a Phase 2 trial of nebokitug in SSc."   ...   Read the full article here. ----- No. 3 CMMB Potential Catalyst - A Major Milestone Completed As Company Aligns With FDA On Design Of Single Phase 3 Registration Study. Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis Single Positive Phase 3 Trial Designed to Support Full Regulatory Approval, For the First Time Providing Regulatory Clarity in PSC and Positioning Nebokitug to Potentially Become the First FDA-Approved Treatment for PSC No Liver Biopsies or Additional Confirmatory Studies Required—Phase 3 Trial Endpoint Is Based on Well-Characterized Clinical Events Associated with PSC Disease Progression Derisked Phase 3 Program Leverages Published PSC Data Associating Reductions in Clinical Events with the Types of Biomarker Improvements Seen in Nebokitug Phase 2 SPRING Trial Advancing Discussions with Potential Strategic Partners Post-FDA Feedback While Preparing for Nebokitug Phase 3 Trial TEL AVIV, Israel, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), ..., today announced the successful completion of its End-of-Phase 2 Meeting with the U.S. Food and Drug Administration (FDA) and alignment with FDA on the design of a single Phase 3 registration study for its lead product candidate nebokitug (CM-101) for the treatment of primary sclerosing cholangitis (PSC). Nebokitug is the drug name recently assigned to CM-101 by the International Nonproprietary Names (INN) program of the World Health Organization. "Successful completion of this major milestone is a huge achievement for Chemomab, for patients and for the larger community combatting PSC, a debilitating and often lethal disorder that has no FDA-approved therapies," said Adi Mor, PhD, co-founder and Chief Executive Officer of Chemomab. "The design of our Phase 3 trial provides, for the first time, regulatory clarity on a streamlined path to potential full regulatory approval based on a single pivotal trial that does not require liver biopsy and includes the most relevant primary efficacy endpoint in PSC. This design allows us to significantly accelerate the potential timeline to full approval since there is no need for additional confirmatory studies. This is also the first time that FDA has agreed to the use of a primary endpoint for PSC comprised of clinical events associated with disease progression, which we and leading experts believe is practical, feasible and well-aligned with clinical practice and the natural history of the disease." Dr. Mor continued, "Importantly, key publications have shown that the reductions in PSC biomarkers in our nebokitug Phase 2 SPRING trial, especially the Enhanced Liver Fibrosis (ELF) and liver stiffness elastography measures, are associated with reductions in clinical events, increasing our confidence in the relevance of this approach for nebokitug and decreasing risk. We are looking forward to reporting topline data from the open label extension portion of the SPRING trial, which is primarily intended to provide additional data on nebokitug's long term safety, before the end of the first quarter. The company is currently in active discussions with potential strategic partners while laying the groundwork for the Phase 3 program, which we could potentially launch before the end of the year." ...   Read the full article here. ----- No. 4 CMMB Potential Catalyst - A Maxim Group Analyst Tags CMMB With A $7 Target! The Maxim Group has built one of the premier proprietary research platforms on Wall Street, with an emphasis on small-cap, micro-cap, and emerging growth companies. Michael Okunewitch, an analyst at Maxim Group covering the biotechnology sector, has set a $7.00 target on Chemomab Therapeutics as of 3/21/25 according to a published report on the company's website. With this $7.00 target, there could be upside potential of over 400% for CMMB from its closing valuation Wednesday. ----- (Nasdaq: CMMB) Recap - 4 Potential Catalysts Lead The Way No. 1 - Volatility Potential Could Be Heightened Due To A Low Float. No. 2 - CMMB Further Confirms Potential For nebokitug As Novel Treatment For SSc. No. 3 - A Major Milestone Completed As Company Aligns With FDA On Design Of Single Phase 3 Registration Study. No. 4 - A Maxim Group Analyst Tags CMMB With A $7 Target! ----- Coverage is officially initiated on Chemomab Therapeutics Ltd. (Nasdaq: CMMB). When updates are available, I'll get them out quickly. Sincerely, Kai Parker StockWireNews (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *StockWireNews.com ("StockWireNews" or "SWN" ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 03/26/2025 and ending on 03/27/2025 to publicly disseminate information about (CMMB:US) via digital communications. Under this agreement, SWN Media LLC has been paid seventeen thousand five hundred USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (CMMB:US). Please see important disclosure information here: https://stockwirenews.com/disclosure/cmmb/#details Unsubscribe Stock Wire News 160 West Camino Real Unit 886 Boca Raton, Florida 33432 United States